Vietnam to cooperate in clinical trial of French Covid treatment medicine
(VOVWORLD) - Deputy Minister of Health Tran Van Thuan held an online working session with France’s Xenothera company on cooperation to conduct the third phase of clinical trial of Xenothera-developed XAV-19 COVID-19 treatment drug and the transfer of XAV-19 production technology to Vietnam.
 Treatment of COVID-19 patients (Photo: VNA)
|
The COVID-19 treatment drug is based on polyclonal antibodies that targets COVID-19 patients with moderate conditions.
The first and second phases of XAV-19 clinical trials’ results showed that the drug is effective and safe in preventing the virus to develop, neutralizing the virus and reducing inflammation in patients. The third phase of XAV-19 clinical trials is being conducted in some European countries.
Odile Duvaux, president of the French pharmaceutical company said his company is willing to cooperate with Vietnam in implementing the third phase of the trials, and to engage in further discussions on the transfer of the drug production technology to Vietnam.